Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.
One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...
Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug
Frustrated by the price of a lifesaving cystic fibrosis treatment sold by Vertex Pharmaceuticals, a group of families is ...
Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...
KING OF PRUSSIA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results ...
While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear ...
StockStory.org on MSN
Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The ...
TipRanks on MSN
Vertex and Moderna’s VX-522 Study: A Potential Breakthrough in Cystic Fibrosis Treatment
This study update could positively impact Vertex Pharmaceuticals and Moderna’s stock performance, as successful results may enhance their competitive position in the cystic fibrosis treatment market.
Read about types of businesses, how to start one, and how to get a business loan Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides ...
The quality of an applicant's personal statement is very important at LSE. The School does not interview for places so this is an applicant’s only opportunity to demonstrate they are a good fit for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback